CLINICAL TRIALS FOR GRIN2B

Participating in clinical trials is an important way to help accelerate therapeutic development. Find more information about the study and future studies below.

GRIN THERAPEUTICS: RAD-GRIN-101

BEELINE STUDY – ENROLLING

ClinicalTrials.gov ID – NCT07224581

The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant.

This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort).

Press Release: https://bit.ly/49Iv2GJ

Letter to the community: https://bit.ly/4qQGdTD

FAQ’s: https://bit.ly/4pxsSyi

Read the results of the Phase 1 trial here.

LUNDBECK: DEEP OCEAN STUDY

The DEEp Ocean Study is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Developmental Epileptic Encephalopathy. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.

Learn how to enroll here.

Disclaimer – GRIN2B Foundation is passing this information along to you for information purposes; please check with your doctor first to see if your child should participate.